Elicio Therapeutics (ELTX) Change in Account Payables (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Change in Account Payables came in at -$460000.0 in Q1 2026, down 115.34% YoY from $3.0 million in Q1 2025, and down 231.05% on a QoQ basis from $351000.0 in Q4 2025.
Elicio Therapeutics (ELTX) Change in Account Payables (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Change in Account Payables data on file, last reported at -$460000.0 in Q1 2026.
- Quarterly Change in Account Payables fell 115.34% year-over-year to -$460000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.8 million (down 230.46% YoY) and the FY2025 annual result came in at -$366000.0, up 89.01% from the prior year.
- Change in Account Payables slipped to -$460000.0 in Q1 2026, from $351000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $3.1 million in Q2 2022 to a low of -$3.5 million in Q3 2025.
- A 5-year average of -$177000.0 and a median of -$172000.0 in 2025 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 554.23% in 2024, down 2265.0% in 2024.
- Tracing ELTX's Change in Account Payables over 5 years: stood at -$282000.0 in 2022, then soared by 85.82% to -$40000.0 in 2023, then plunged by 2265.0% to -$946000.0 in 2024, then surged by 137.1% to $351000.0 in 2025, then sank by 231.05% to -$460000.0 in 2026.
- The last three Change in Account Payables figures came in at -$460000.0 (Q1 2026), $351000.0 (Q4 2025), and -$3.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | 627,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 627,000.00 |
| Jun 30, 2026 | 627,000.00 |
| Mar 31, 2026 | -460,000.00 |
| Mar 31, 2026 | -460,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Sep 30, 2025 | -3.54 Mn |
| Sep 30, 2025 | -3.54 Mn |
| Jun 30, 2025 | -172,000.00 |
| Jun 30, 2025 | -172,000.00 |
| Mar 31, 2025 | 3.00 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | -946,000.00 |
| Dec 31, 2024 | -946,000.00 |
| Sep 30, 2024 | 929,000.00 |
| Sep 30, 2024 | 929,000.00 |
| Jun 30, 2024 | -50,000.00 |
| Jun 30, 2024 | -50,000.00 |
| Mar 31, 2024 | -3.26 Mn |
| Mar 31, 2024 | -3.26 Mn |